Akero Therapeutics press release (NASDAQ:AKRO): Q2 GAAP EPS of -$0.86 beats by $0.11.
Akero’s cash, cash equivalents and short and long-term marketable securities as of June 30, 2025, were $1,086.2 million.
Akero believes that its cash, cash equivalents and short and long-term marketable securities will be sufficient to fund its current operating plan into 2028.
Akero’s cash, cash equivalents and short and long-term marketable securities as of June 30, 2025, were $1,086.2 million.
Akero believes that its cash, cash equivalents and short and long-term marketable securities will be sufficient to fund its current operating plan into 2028.
